Compare USEG & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | PSTV |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 46.4M |
| IPO Year | N/A | N/A |
| Metric | USEG | PSTV |
|---|---|---|
| Price | $1.01 | $0.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.50 | ★ $6.75 |
| AVG Volume (30 Days) | 1.2M | ★ 20.0M |
| Earning Date | 03-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,484,000.00 | $5,258,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | $57.52 | $12.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.16 |
| 52 Week High | $2.75 | $2.31 |
| Indicator | USEG | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 35.53 |
| Support Level | $0.99 | $0.22 |
| Resistance Level | $1.09 | $0.28 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.08 | 72.56 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).